202 COUSTEAU PLACE, DAVIS, X1
Arcadia Biosciences Receives Nasdaq Delisting Notice Due to Equity Shortfall
Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
News
Annual Report to Security Holders
Material disclosure
Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Consolidated Balance Sheets (Unaudited)
Deloitte Dismissed as Independent Auditor for Arcadia Biosciences
Q2
Q1
Amended Annual Report
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Registration of Securities under Section 12(g)